<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859131</url>
  </required_header>
  <id_info>
    <org_study_id>thymo vs IL2</org_study_id>
    <nct_id>NCT00859131</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists</brief_title>
  <official_title>Rabbit Anti-thymocyte Globulin Versus IL2 Receptor Antagonists in Combination With Tacrolimus, Corticosteroids and Mycophenolate Mofetil in a Predominantly High Risk Kidney Transplant Population.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of induction therapy with
      Thymoglobulin in comparison with IL2 receptor antagonists (daclizumab or basiliximab).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 12 month, prospective, randomized, single center, open-label study to evaluate the safety
      and efficacy of Rabbit anti-thymocyte globulin versus IL2 receptor antagonists in combination
      with tacrolimus, corticosteroids and mycophenolate mofetil in a predominantly high risk
      kidney transplant population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Efficacy Will be Defined as the Number of Patients With Biopsy Proven Acute Rejection at One Year Post-transplant.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring Antilymphocyte Therapy for Acute Rejection.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Survival at One Year Post-transplant</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Post-transplant Infections, Including, But Not Limited to, CMV Infection and Disease, BK Infection and Nephropathy, Other Opportunistic Infections, Urinary Tract Infections, Pneumonia, and Sepsis</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Post-transplant Malignancies, Including Post-transplant Lymphoproliferative Disease (PTLD) and Skin Cancers.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Leukopenia, Defined as a Total White Blood Cell Count of Less Than 2,000 Cells/mm3</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Thrombocytopenia, Defined as a Platelet Count of Less Than 100,000 Cells/mm3</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Thymoglobulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receiving Thymoglobulin as induction agent in renal transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zenapax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subject who will receive daclizumab or basiliximab as induction agent in renal transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit Antithymocyte globulin</intervention_name>
    <description>1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4</description>
    <arm_group_label>Thymoglobulin</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclizumab</intervention_name>
    <description>1.0 mg/kg pre-op and 1.0 mg/kg on Day 7</description>
    <arm_group_label>Zenapax</arm_group_label>
    <other_name>daclizumab, zenapax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients between 18 and 75 years of age

          -  Male or female patients who are primary or repeat cadaveric, living unrelated or non-
             Human leukocyte antigen (HLA) identical living related donor renal transplant
             recipients

          -  Female patients of child bearing potential must have a negative urine or serum
             pregnancy test within the past 48 hours prior to study inclusion.

          -  The patient has given written informed consent to participate in the study

        Exclusion Criteria:

          -  Patient has previously received or is receiving an organ transplant other than a
             kidney.

          -  Patients who are recipients of a multiple organ transplant.

          -  Patient has received a primary or re-transplant from an HLA-identical living donor.

          -  Any positive cross-match.

          -  Patient is the recipient of a pediatric donor kidney from a pediatric donor aged 8
             years or less.

          -  Patient has received an ABO incompatible donor kidney.

          -  Recipient or donor is known to be seropositive for hepatitis C virus (HCV) or B virus
             (HBV) except for hepatitis B surface antibody positive.

          -  Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV).

          -  Patient has uncontrolled concomitant infection or any other unstable medical condition
             that could interfere with the study objectives.

          -  Patients with thrombocytopenia (&lt;75,000/mm3 ), with an absolute neutrophil count of &lt;
             1,000/mm3); and/or leucopoenia (&lt; 2,000/mm3), or anemia (hemoglobin &lt; 6 g/dL) prior to
             study inclusion.

          -  Patient is taking or has been taking an investigational drug in the 30 days prior to
             transplant.

          -  Patient has a known hypersensitivity to tacrolimus, mycophenolate mofetil, rabbit
             anti-thymocyte globulin, daclizumab or corticosteroids.

          -  Patients with severe diarrhea or other gastrointestinal disorders that might interfere
             with their ability to absorb oral medication.

          -  Patients with a history of malignancy within the last five years, except for
             successfully excised squamous or basal cell carcinoma of the skin.

          -  Patient is pregnant or lactating, where pregnancy is defined as the state of a female
             after conception and until the termination of gestation, confirmed by positive human
             Chorionic Gonadotropin (hCG) laboratory test.

          -  Women of childbearing potential must use two reliable forms of contraception
             simultaneously, unless they are status post bilateral tubal ligation, bilateral
             oophorectomy, or hysterectomy. Effective contraception must be used before beginning
             study drug therapy, for the duration of the study and for 6 weeks following completion
             of the study.

          -  Patient has any form of substance abuse, psychiatric disorder or a condition that, in
             the opinion of the investigator, may invalidate communication with the investigator.

          -  Inability to cooperate or communicate with the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth D Chavin, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole Pilch, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Taber, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prabhakar Baliga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2009</study_first_posted>
  <results_first_submitted>May 14, 2015</results_first_submitted>
  <results_first_submitted_qc>March 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 26, 2016</results_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Daclizumab</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Thymoglobulin</title>
          <description>Subjects receiving Thymoglobulin as induction agent in renal transplantation
Rabbit Antithymocyte globulin: 1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4</description>
        </group>
        <group group_id="P2">
          <title>Zenapax</title>
          <description>subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
Daclizumab: 1.0 mg/kg pre-op and 1.0 mg/kg on Day 7</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Thymoglobulin</title>
          <description>Subjects receiving Thymoglobulin as induction agent in renal transplantation
Rabbit Antithymocyte globulin: 1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4</description>
        </group>
        <group group_id="B2">
          <title>Zenapax</title>
          <description>subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
Daclizumab: 1.0 mg/kg pre-op and 1.0 mg/kg on Day 7</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="98"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="13"/>
                    <measurement group_id="B2" value="49" spread="14"/>
                    <measurement group_id="B3" value="50.2" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Efficacy Will be Defined as the Number of Patients With Biopsy Proven Acute Rejection at One Year Post-transplant.</title>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thymoglobulin</title>
            <description>Subjects receiving Thymoglobulin as induction agent in renal transplantation
Rabbit Antithymocyte globulin: 1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4</description>
          </group>
          <group group_id="O2">
            <title>Zenapax</title>
            <description>subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
Daclizumab: 1.0 mg/kg pre-op and 1.0 mg/kg on Day 7</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Efficacy Will be Defined as the Number of Patients With Biopsy Proven Acute Rejection at One Year Post-transplant.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring Antilymphocyte Therapy for Acute Rejection.</title>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thymoglobulin</title>
            <description>Subjects receiving Thymoglobulin as induction agent in renal transplantation
Rabbit Antithymocyte globulin: 1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4</description>
          </group>
          <group group_id="O2">
            <title>Zenapax</title>
            <description>subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
Daclizumab: 1.0 mg/kg pre-op and 1.0 mg/kg on Day 7</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Antilymphocyte Therapy for Acute Rejection.</title>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Survival at One Year Post-transplant</title>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thymoglobulin</title>
            <description>Subjects receiving Thymoglobulin as induction agent in renal transplantation
Rabbit Antithymocyte globulin: 1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4</description>
          </group>
          <group group_id="O2">
            <title>Zenapax</title>
            <description>subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
Daclizumab: 1.0 mg/kg pre-op and 1.0 mg/kg on Day 7</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Survival at One Year Post-transplant</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Post-transplant Infections, Including, But Not Limited to, CMV Infection and Disease, BK Infection and Nephropathy, Other Opportunistic Infections, Urinary Tract Infections, Pneumonia, and Sepsis</title>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thymoglobulin</title>
            <description>Subjects receiving Thymoglobulin as induction agent in renal transplantation
Rabbit Antithymocyte globulin: 1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4</description>
          </group>
          <group group_id="O2">
            <title>Zenapax</title>
            <description>subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
Daclizumab: 1.0 mg/kg pre-op and 1.0 mg/kg on Day 7</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Post-transplant Infections, Including, But Not Limited to, CMV Infection and Disease, BK Infection and Nephropathy, Other Opportunistic Infections, Urinary Tract Infections, Pneumonia, and Sepsis</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Post-transplant Malignancies, Including Post-transplant Lymphoproliferative Disease (PTLD) and Skin Cancers.</title>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thymoglobulin</title>
            <description>Subjects receiving Thymoglobulin as induction agent in renal transplantation
Rabbit Antithymocyte globulin: 1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4</description>
          </group>
          <group group_id="O2">
            <title>Zenapax</title>
            <description>subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
Daclizumab: 1.0 mg/kg pre-op and 1.0 mg/kg on Day 7</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Post-transplant Malignancies, Including Post-transplant Lymphoproliferative Disease (PTLD) and Skin Cancers.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Leukopenia, Defined as a Total White Blood Cell Count of Less Than 2,000 Cells/mm3</title>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thymoglobulin</title>
            <description>Subjects receiving Thymoglobulin as induction agent in renal transplantation
Rabbit Antithymocyte globulin: 1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4</description>
          </group>
          <group group_id="O2">
            <title>Zenapax</title>
            <description>subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
Daclizumab: 1.0 mg/kg pre-op and 1.0 mg/kg on Day 7</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Leukopenia, Defined as a Total White Blood Cell Count of Less Than 2,000 Cells/mm3</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Thrombocytopenia, Defined as a Platelet Count of Less Than 100,000 Cells/mm3</title>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thymoglobulin</title>
            <description>Subjects receiving Thymoglobulin as induction agent in renal transplantation
Rabbit Antithymocyte globulin: 1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4</description>
          </group>
          <group group_id="O2">
            <title>Zenapax</title>
            <description>subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
Daclizumab: 1.0 mg/kg pre-op and 1.0 mg/kg on Day 7</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Thrombocytopenia, Defined as a Platelet Count of Less Than 100,000 Cells/mm3</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Thymoglobulin</title>
          <description>Subjects receiving Thymoglobulin as induction agent in renal transplantation
Rabbit Antithymocyte globulin: 1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4</description>
        </group>
        <group group_id="E2">
          <title>Zenapax</title>
          <description>subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
Daclizumab: 1.0 mg/kg pre-op and 1.0 mg/kg on Day 7</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>BK Viremia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>CMV</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kenneth Chavin, MD, PhD</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-3368</phone>
      <email>chavinkd@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

